Protalix BioTherapeutics, Inc. (FRA:PBDA)

Protalix BioTherapeutics Statistics

Total Valuation

FRA:PBDA has a market cap or net worth of EUR 143.12 million. The enterprise value is 124.90 million.

Market Cap	143.12M
Enterprise Value	124.90M

Important Dates

The next estimated earnings date is Tuesday, March 17, 2026.

Earnings Date	Mar 17, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	80.42M
Shares Outstanding	n/a
Shares Change (YoY)	+15.89%
Shares Change (QoQ)	-0.56%
Owned by Insiders (%)	10.63%
Owned by Institutions (%)	17.87%
Float	61.35M

Valuation Ratios

The trailing PE ratio is 31.13.

PE Ratio	31.13
Forward PE	n/a
PS Ratio	2.72
PB Ratio	3.17
P/TBV Ratio	3.17
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.10, with an EV/FCF ratio of -12.53.

EV / Earnings	27.17
EV / Sales	2.35
EV / EBITDA	15.10
EV / EBIT	22.82
EV / FCF	-12.53

Financial Position

The company has a current ratio of 3.03, with a Debt / Equity ratio of 0.15.

Current Ratio	3.03
Quick Ratio	2.00
Debt / Equity	0.15
Debt / EBITDA	0.85
Debt / FCF	-0.70
Interest Coverage	7.82

Financial Efficiency

Return on equity (ROE) is 12.64% and return on invested capital (ROIC) is 8.02%.

Return on Equity (ROE)	12.64%
Return on Assets (ROA)	5.53%
Return on Invested Capital (ROIC)	8.02%
Return on Capital Employed (ROCE)	10.56%
Revenue Per Employee	247,447
Profits Per Employee	21,584
Employee Count	213
Asset Turnover	0.86
Inventory Turnover	1.37

Taxes

In the past 12 months, FRA:PBDA has paid 929,007 in taxes.

Income Tax	929,007
Effective Tax Rate	16.81%

Stock Price Statistics

The stock price has decreased by -18.10% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-18.10%
50-Day Moving Average	1.63
200-Day Moving Average	1.63
Relative Strength Index (RSI)	69.60
Average Volume (20 Days)	163

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.79

Income Statement

In the last 12 months, FRA:PBDA had revenue of EUR 52.71 million and earned 4.60 million in profits. Earnings per share was 0.06.

Revenue	52.71M
Gross Profit	30.32M
Operating Income	5.43M
Pretax Income	5.53M
Net Income	4.60M
EBITDA	6.63M
EBIT	5.43M
Earnings Per Share (EPS)	0.06

Balance Sheet

The company has 25.03 million in cash and 6.97 million in debt, with a net cash position of 18.06 million.

Cash & Cash Equivalents	25.03M
Total Debt	6.97M
Net Cash	18.06M
Net Cash Per Share	n/a
Equity (Book Value)	45.09M
Book Value Per Share	0.56
Working Capital	37.98M

Cash Flow

In the last 12 months, operating cash flow was -8.55 million and capital expenditures -1.41 million, giving a free cash flow of -9.97 million.

Operating Cash Flow	-8.55M
Capital Expenditures	-1.41M
Free Cash Flow	-9.97M
FCF Per Share	n/a

Margins

Gross margin is 57.54%, with operating and profit margins of 10.30% and 8.72%.

Gross Margin	57.54%
Operating Margin	10.30%
Pretax Margin	10.49%
Profit Margin	8.72%
EBITDA Margin	12.58%
EBIT Margin	10.30%
FCF Margin	n/a

Dividends & Yields

FRA:PBDA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.89%
Shareholder Yield	-15.89%
Earnings Yield	3.21%
FCF Yield	-6.96%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on December 20, 2019. It was a reverse split with a ratio of 0.1.

Last Split Date	Dec 20, 2019
Split Type	Reverse
Split Ratio	0.1

Scores

FRA:PBDA has an Altman Z-Score of -1.89 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.89
Piotroski F-Score	5